What is Wedbush’s Forecast for PepGen FY2028 Earnings?

PepGen Inc. (NASDAQ:PEPG) – Investment analysts at Wedbush lifted their FY2028 earnings per share (EPS) estimates for shares of PepGen in a report released on Monday, December 16th. Wedbush analyst L. Chico now anticipates that the company will post earnings per share of ($1.85) for the year, up from their previous estimate of ($2.08). Wedbush has a “Outperform” rating and a $12.00 price objective on the stock. The consensus estimate for PepGen’s current full-year earnings is ($2.84) per share.

PEPG has been the topic of a number of other reports. HC Wainwright restated a “buy” rating and set a $26.00 target price on shares of PepGen in a research report on Friday, November 8th. Bank of America lowered PepGen from a “neutral” rating to an “underperform” rating and set a $3.00 price objective on the stock. in a report on Monday, December 16th.

PepGen Stock Performance

PEPG stock opened at $3.63 on Thursday. PepGen has a one year low of $2.90 and a one year high of $19.30. The firm’s fifty day moving average is $5.96 and its 200 day moving average is $10.33. The firm has a market cap of $118.32 million, a PE ratio of -1.22 and a beta of 1.56.

Institutional Trading of PepGen

A number of institutional investors and hedge funds have recently modified their holdings of PEPG. Suvretta Capital Management LLC lifted its stake in PepGen by 9.2% in the 3rd quarter. Suvretta Capital Management LLC now owns 1,660,932 shares of the company’s stock valued at $14,201,000 after buying an additional 140,000 shares in the last quarter. Sofinnova Investments Inc. lifted its position in shares of PepGen by 11.4% in the second quarter. Sofinnova Investments Inc. now owns 561,128 shares of the company’s stock valued at $8,956,000 after acquiring an additional 57,504 shares in the last quarter. Janus Henderson Group PLC boosted its stake in shares of PepGen by 331.2% in the third quarter. Janus Henderson Group PLC now owns 2,336,516 shares of the company’s stock worth $20,012,000 after acquiring an additional 1,794,641 shares during the last quarter. American Century Companies Inc. increased its position in shares of PepGen by 19.9% during the second quarter. American Century Companies Inc. now owns 20,028 shares of the company’s stock worth $320,000 after purchasing an additional 3,326 shares in the last quarter. Finally, Renaissance Technologies LLC acquired a new position in PepGen in the 2nd quarter valued at $192,000. Hedge funds and other institutional investors own 58.01% of the company’s stock.

PepGen Company Profile

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.